Clinical Trial

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-16.
Trial Details
NCT Number NCT06005870
Lead Sponsor Huazhong University of Science and Technology
Conditions Diffuse Large B Cell Lymphoma
Enrollment 41 participants
Start Date 2022-11-26
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-18